Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, connective tissue neoplasm, fibrosarcoma, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, sarcoma	Recruiting	Phase 2	2026-08-24		NCT05253131

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Children's Hospital of Philadelphia	215
Congressionally Directed Medical Research Programs	87
University of Alabama at Birmingham	467

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's of Alabama	Birmingham	United States	1